Tonix Pharmaceuticals Holding Corporation (TNXP) Quote

On the wires, Zacks gives TNXP a target price of $2.50 @ 10:05 this morn

Welcome back Tyrue!!! Great to see you again. The boys are back in town it seems. Let’s make history again here with $TNXP!!

NEWS: https://ir.tonixpharma.com/news-events/press-releases/detail/1539/tonix-pharmaceuticals-announces-expansion-of-leadership

Looks like Tonix's got a product to market soon. 🚀🚀🚀

Good to be back and fully invested in the same stock as you again, my friend!
Another scouring of the penny market led me here, and to discover-- voila!  -- that my favorite Multi Bag maestro is already here.
I'm all for another instance of deja vu-room vroom! too. As, when we joined in on that previous stock together.(which DID in fact run up 10 bags between June 2021 and summer of 2022, before its crash) that happened to be the year immediately following a contentious election, exactly four years ago, after which we all, finally, put the political strife of a presidential election year and inauguration behind us, and turned our attention back fully to the multiple penny stocks making epic runups in 2021. 
May 2025 bring us similar luck! 
And why not? 
Aren't the ups and downs of the market supposed to be cyclical? I say yes, let's go!

On 16 Oct, TNXP announced they submitted their NDA, with a 60 day 'response' from
the fda anticipated regarding its 'acceptance' (or not).

That 60 day window is 'closing down' and the share price is 'coiling' at
around 19 cents/sh. With its Moving Average line now closing in on the 19 cent
price range.

Yep, like a coiled 'snake' getting wound tighter and tighter. Just waiting for something
to trigger its release (with the potential to go either way depending on what the fda says)

Disclaimer: bullish based on what they company has stated the PH 3s has demonstrated, but 'cautious' not to overcommit despite my desire to do so..

We're moving to the moon. Yes let's go to the moon with zero resistance and a golden donut in our hand,

Events soon and split canceled could move thru resistance,astronomical potential = huge greed

$3 per share would be fantastic.

How about we start with something 'reasonable' to
begin with??

Like maybe 50 cents if their NDA is accepted for review
Like maybe $3 if they are approved (market cap gets 'inflated' at $3)

and see what sales then justifies...

Or you could help us see what the $96 is based on. Call me curious (smile)
Unless your $96 is based on a r/split occurring to cut down the share count, help
make the share price 'attractive' to bigger players. But with around 180 Million
authorized, but only 22 Million in the float (available for trading), a r/split is going to be
tough to do unless its something like a 1-3 or 1-4 unless they then sell a bunch of shares
to raise cash and expand the float..

But at 50 cents? a nice 150% from 20 cents
at $3/sh? A very nice 1400% return from 20 cents..

TNXP. FIRST CASE OF MPOX 1 IN CANADIAN REPORTED 800 PM FRIDAY..THEY ONLY HAD MPOX 2 IN PAST REPORTS

TNXP. FIRST CASE OF MPOX 1 IN CANADIAN REPORTED 800 PM FRIDAY..THEY ONLY HAD MPOX 2 IN PAST REPORTS

TNXP. PRICE TARGET 96 DOLLARS PICTURE OF CHART POSTED ON STOCKWITS

TNXP. PRICE TARGET 96 DOLLARS PICTURE OF CHART POSTED ON STOCKWITS

Volume has picked up here tremendously. This could explode at any moment imo. Locked and loaded with about 60,000 shares.

Tnxp. Price target of 96 dollars chart picture on stockwits.....buy a house with 1 thousand dollars in investment

https://investorshub.advfn.com/secure/post_new.aspx?board_id=26243.....price target of 96 dollars

I agree. Less than 30 days now to the fdas decision on
the NDA submission.

No secret there are 'some' that trade biotech company
'events'.

Been telling the few that I chat with, IF the NDA is accepted
for review, expect a little bounce in the share price on the news.

Again, I have never invested in a company making a 'pain reliever' before.
So a little wary with regard to the robustness of the clinical trials they ran in
terms of will they be 'good enough'. And most of my biotech investments
tho, have centered on finding a development that fits a serious NEED vs
is just a bit better than whats already out there (that in this case, doesn't seem
to 'work' for people)

disclaimer: own shares, and might be time to make that one last add

Something Brewing 1 way or another

I hear ya

I am expecting another reverse split down the road to help get the share price up to the $5/sh range..

But hopefully they hold off doing it until the share price has moved up a bit and they have/are expecting news
that will then support/draw interest for the shares..

Still no idea why it ran other than they talked about their developments AGAIN, or someone decided to spark
an AHours frenzy knowing that in the post market, movements are magnified..

And have to wonder what those that paid up to 32 cents/sh this morn in the pre market are thinking..

Maybe turning right around and selling huge volume too

SOMEBODY IS BUYING.....HUGE VOLUME !!!

Does anyone know if they decided to do another r/s back in October during their meeting? Or modify their share structure?

I have bought and watched this stock since Covid hit 2021 in a 401k plan at my job and I have lost a lot especially every r/s

Hope it runs but I’m very hesitant to believe they not going to do another r/s

So yesterday in AH it gained 0.0777!

With 7 reverse splits and a penny stock thrill,
Today's volume might hit a billion — for real!
High risk, high ride, it's a crazy sensation,
Hold on tight for the stock's wild vacation!

I may have picked up 30,000 shares+ today. We are going to the moon.

never know . watching

We finally closed above the 50 dma. It's got some running room now.

TNXP: Soaring in the Post-Market, right now. (See below what COPILOT as to say about it.)

"Why is TNXP stock soaring by 68% in the Post-M right now, 11-19-24? Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) stock is soaring today due to positive investor sentiment ahead of their Chief Operating Officer, Jessica Morris, presenting at the Winter 2024 Investor Summit. This event is generating excitement and optimism among investors about the company's future prospects1. Additionally, Tonix Pharmaceuticals has been making significant strides in its product pipeline, including the development of TNX-102 SL for fibromyalgia and TNX-4200 for antiviral treatments. These advancements are likely contributing to the stock's surge. Are you considering investing in TNXP, or are you just curious about the recent developments?"
https://www.tonixpharma.com/jessica-edgar-morris/
/////////////////////////////////////////////////////////////////////////////////////////

TNXP......................https://stockcharts.com/h-sc/ui?s=TNXP&p=W&b=5&g=0&id=p86431144783

Less than 30 days now left in the 60 day window for the fda to
decide whether or not to accept their NDA submission.

The 'story' has been told, its out there. And a lot of shares are being
'churned' on a daily basis. Got 6 MILLION already today in volume for example.

Don't think the 'story' is going to do very much at this point.

Think the only way this thing gets off the 'floor' so to speak is for the 'approval' cycle to
commence. And the first step is their NDA being 'accepted' for review.

disclaimer: own shares, APS around 17.5 cents... 50 cents is my first target price based on
acceptance of the submission.. (although won't be surprised if it takes some months leading up
a PDUFA day IF they get one)

This could give us a bump up.
https://www.nasdaq.com/press-release/tonix-pharmaceuticals-present-winter-2024-investor-summit-virtual-2024-11-18

I am going with 50 cents IF their NDA is 'accepted' by the fda. Believe thats now down to
around 30 days left in the standard 60 day window post submission.

Then given the share count outstanding (somewhere around 140 Million shares/$18 Mil MARKET CAP),
looking for around $3/sh IF approved (Market Cap: $420 Million)...

And also expecting a REVERSE SPLIT down the road simply to reduce the share count and jack up the
share price over $5 to help draw in the bigger investors.. But thats likely down the road closer to the
approval date when that can help hold up the share price.

Good luck

disclaimer: own shares, plan to add more, but not until this starts to show renewed interest for the shares.

https://www.sec.gov/ix?doc=/Archives/edgar/data/1430306/000183988224038453/tnxp-8k_110824.htm
TNX-1700 (hTFF2-HSA) appears to be a very promising candidate for the treatment of gastric and colorectal cancer, with an innovative mechanism of action that addresses immune inhibition in the tumor microenvironment. The synergy with immune checkpoint inhibitors, favorable preclinical results and the blood-life prolongation approach through fusion with albumin suggest that this drug could represent an effective new therapeutic option, particularly for patients who do not respond to conventional treatments.
Dr. Timothy Wang leading the research, increasing credibility and the possibility of long-term success.
Innovative mechanism of action:
Reduce immune inhibition in the tumor microenvironment (TME), in particular by reducing MDSCs (myeloid-derived suppressor cells) that prevent the effectiveness of immune responses against the tumor.
Synergy with immune checkpoint inhibitors (anti-PD-1):
Greater combined efficacy: TNX-1700 enhances the immune response when combined with anti-PD-1 drugs, as shown in preclinical models of colorectal and gastric cancers.
Promising preclinical evidence:
Robust data in animal models of orthotopic and metastatic tumors showing significant reduction in tumor growth, metastasis and improved survival.
Increased tumor-infiltrating CD8+ T cells, suggesting an improved immune response.
Albumin technology for blood life extension:
Fusion with albumin increases the pharmacokinetics of the drug, reducing the frequency of administration and improving the duration of the therapeutic effect.
it's all nice… very large market! but it takes a lot of money to approve it! maybe in another 7 R/S

If not more of a pop in sp .

This has a good chance at a $20 to $30 pop next year IF FDA approves the "The US Food and Drug Administration (FDA) has granted Fast Track designation to Tonix Pharmaceuticals’ Tonmya (cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia." gets a green light for sales. At this current price of .1427, to me it's worth the risk.just For that.
" https://www.proactiveinvestors.co.uk/companies/news/1059401/tonix-pharmaceuticals-ceo-discusses-new-drug-application-for-fibromyalgia-treatment-1059401.html " Not to mention the DoD military contract and with the pending NATO war with russia and the situation in Asia, " https://finance.yahoo.com/news/tonix-pharmaceuticals-receives-first-contract-120000292.html " And the monkey pox vaccine trials initiative " https://ir.tonixpharma.com/news-events/press-releases/detail/1530/tonix-pharmaceuticals-presented-data-on-potential-mpox " " https://www.tonixpharma.com/pipeline-2/ "

Gobble. Gobble

Pretty big 'market' for a treatment that 'works'. That has a 'need' for one
that works. Never realized how big a problem fibromyalgia 'is'..

https://www.fmaware.org/fibromyalgia-the-economic-burden/#:~:text=Prominent%20fibromyalgia%20researchers%20and%20specialists%20estimate%20the%20costs,loss%20of%201-2%25%20of%20the%20nation%C3%A2%E2%82%AC%E2%84%A2s%20overall%20productivity.

Fibromyalgia: the Economic Burden
The cost of fibromyalgia to both the individual and to society is extensive. A 2007 study found that 34% of fibromyalgia patients spend between $100- $1,000 per month above their insurance to see a healthcare professional. Prominent fibromyalgia researchers and specialists estimate the costs in the U.S. between $12-14 billion each year and accounts for a loss of 1-2% of the nation’s overall productivity.

Looks like it’s ready to go back up again,I am watching the shares to borrow closely,when they start dropping it will start ripping again

good point

YOU ARE ON RIGHT TRACK.

Looking at the 3 Clinical Trials to see what 'happened'..

The one that ended in 2020 passed based on the end points.

The 2nd trial, RALLY, that followed did NOT meet the end points and I wanted to know
WHY it didn't, WHY it failed. At this link is an explanation for why it didn't pass. And tho
it didn't 'pass' cause of 'adverse' effects (see the write up for their explanation), they did state
that the results were otherwise 'consistent' with the first trial results.

https://ir.tonixpharma.com/news-events/press-releases/detail/1304/tonix-pharmaceuticals-announces-phase-3-rally-study-results

So they then started the RESILIENT trial that then passed.

So to sum it up, they ran 3 trials that based on their analysis met the trial endpoints with enough
stat significance to pass, and warrant their NDA submission that just took place. So given this, it
would APPEAR that this should be enough for the fda to accept the submission for review. The only
question that remains at this point is, was the trial 'robust' enough for the fda to say, we agree with the data
that the development does achieve its goal, that it helps people.

TBD'd.. NOTE: this review of the trials, the outcome was my priority when I had a chance even tho
I had already bought shares based on what I initially read. After what just happened to another favorite
of mine (ATNM where the fda concured in trial passed, but they screwed the company over by saying, for
reasons, you now have to run another PH 3 despite the evidence that the development WORKS/HELPS people)
I no longer can trust the trial results even if they are really good, to be 'good' enough anymore..

disclaimer: own shares

Real question is, is it an 'opportunity' in the making??

Not the first time I have bottom 'fed' something that got
pounded down, but had POTENTIAL to rise from the ashes..

Yes, a R/S (1-32 if memory serves me right)
was done in June/July...

Reportedly only around 22 Mil shares in the float. Pretty
tough to do a r/spilt on that..

recent move, Tonix Pharmaceuticals Receives First Contract Payment from U.S. Department of Defense for Accelerated Development of Broad-Spectrum Antivirals with the Defense Threat Reduction Agency (DTRA)
10/17/2024 08:00:00 AM

DOWNER, BIGTIME



[-chart]www.stockscores.com/chart.asp?TickerSymbol=TNXP&TimeRange=180&Interval=d&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=&Band=&avgType1=&movAvg1=&avgType2=&movAvg2=&Indicator1=None&Indicator2=None&Indicator3=None&Indicator4=None&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen[/chart]

I THINK A REVERSE SPLIT. Tonix Pharmaceuticals Holding Corp

I THINK DONE BEFORE.

Financials, shares outstanding...Market cap..

OK, like a lot of baby bios with an idea they are trying to push
across the finish line, they are financially strapped for cash. So
even if the fda accepts their NDA, expecting them to do a few more
secondarys/ATMs to raise cash (ie, dilution). But it is an evil
necessity and long term its impact will be on the target price it might
eventually get.

Shares outstanding: see on Yahoo its 22 Mil in the FLOAT, but 140 Mil
'authorized' (available for use in an ATM??)

Market Cap: at least its 'reasonable' vs way overvalued.

Care to enlighten on the point you might be trying to make?
Thanks.

Cause myself for example, am focused on whats possible going forward..
Whats already happened has the share price sub 20 cents.

and the END of the chart that shows a little 'activity' taking place hinting that
maybe the sell off has run its course..

Figure IF the fda accepts their NDA for consideration? The news is bound to
get someones attention.. Thats the first hurdle to overcome..

When it comes to 'luck', I agree, I don't like
to RELY on it being the reason something
goes 'right'..

But in this world called the market, and many facets of life??
Too many things we can't control or forsee coming at us
when we least expect it.

Often, we lack enough information to do anything but
make an educated guess. And its that lack of info
that ends up biting us..

disclaimer: own shares....